在FDA审查后,萨雷普塔恢复了对步行患者的杜申治疗Elevidys的运输. Sarepta resumes shipments of Duchenne treatment Elevidys for walking patients after FDA review.

Sarepta Therapeutics 已获得 FDA 的许可，可以恢复其杜氏肌营养不良症治疗药物 Elevidys 的运输，用于仍然可以行走的患者。 Sarepta Therapeutics has been permitted by the FDA to resume shipments of its Duchenne muscular dystrophy treatment, Elevidys, for patients who can still walk. 该公司在两名青少年死亡后暂停了货运,但林业发展局的结论是,一名8岁儿童最近的死亡与治疗无关。 The company had paused shipments following the deaths of two teenagers, but the FDA concluded that an 8-year-old's recent death was unrelated to the treatment. Sarepta将继续与林业发展局合作,为无法行走的病人制定安全措施。 Sarepta will continue to work with the FDA on safety measures for patients who cannot walk.